+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are studying the clinical and health outcomes of amivantamab-containing treatments for people with common EGFR-mutated advanced non-small cell lung cancer NSCLC. NSCLC is the most common type of lung cancer and can spread to other parts of the body. This observational study looks at how these treatments work in real-world clinical settings for patients with specific EGFR mutations. Participants include those with advanced NSCLC who have EGFR exon 19 deletions or exon 21 L858R mutations. Two groups are observed one receiving amivantamab combined with carboplatin and pemetrexed after previous therapy failure, and another receiving amivantamab with lazertinib as first-line treatment. No study drugs are provided data is collected from routine medical care. During the study, researchers collect data on treatment duration, progression-free survival, overall survival, adverse events, dose changes, and medication use for up to about 60 months. Quality of life is assessed using the SKINDEX and EORTC QLQ-C30 questionnaires. The study tracks how patients respond to treatment and monitors safety outcomes, with participation lasting several years.

Age: 18Years +All Genders
90 locations
R

Actively Recruiting

This research aims to gather a large group of patients suspected of having coronary artery disease CAD who underwent Computed Tomography Coronary Angiography CTCA to better understand how CTCA helps in identifying the presence and severity of CAD and predicting patient outcomes. The study focuses on assessing the added value of CTCA to current methods in determining disease burden and cardiovascular risk. It is an observational retrospective study analyzing data collected from patients evaluated with CTCA over the past several years. Patients included in the study had CTCA performed using at least 64-slice CT technology or 16-slice with more than 4 years follow-up and had a calcium score available. The study collects data retrospectively from institutional databases, including clinical history, CTCA results, and follow-up records. Patients were classified based on CTCA findings into groups with normal arteries, non-obstructive CAD, or obstructive CAD. Data include detailed CT scanning protocols and administration of medications like beta-blockers and nitroglycerine during imaging. Participants information, such as cardiovascular risk factors and symptoms, was collected from clinical databases and interviews. Outcomes tracked include major adverse cardiovascular events MACE, coronary revascularizations, and shifts in cardiovascular risk categories. Follow-up data were obtained through outpatient visits, phone contacts, and medical records review, with a minimum follow-up of 6 to 12 months. Researchers analyze outcomes using various statistical methods to identify predictors of risk and the incremental value of CTCA in prognosis.

Age: 18Years +All Genders
11 locations
P

Actively Recruiting

Researchers are studying women with newly diagnosed luminal B or triple-negative breast cancer who are candidates for neoadjuvant therapy. The trial evaluates the effects of a preoperative, unsupervised exercise training program on exercise capacity, immune response, autonomic nervous system regulation, cardiovascular health, and tumor aggressiveness before surgery. This study aims to improve functional capacity and explore biological markers related to tumor progression, inflammation, and immune response. Participants are randomly assigned to two groups. Both groups receive lifestyle counseling with recommendations for an active lifestyle, nutrition, stress management, and other health habits. The intervention group also follows a personalized 16-week aerobic and resistance exercise program during neoadjuvant treatment. Participants wear a wrist-worn device to monitor adherence to physical activity. After the intervention, all undergo planned surgery followed by routine clinical care and two follow-up assessments. Throughout the study, researchers collect urine, blood, stool, and tumor biopsy samples at baseline and before surgery to assess exercise capacity, tumor response, inflammatory and metabolic markers, body composition, autonomic function, and quality of life. Overall and disease-free survival are evaluated during follow-ups. Patient-reported outcomes and functional and psychosocial parameters are also measured to understand the impact of the exercise program.

Age: 18Years +FEMALEPhase Not Applicable
2 locations